Compare Essex Property Trust, Inc. (ESS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Essex Property Trust, Inc. trades at $297.51 (market cap $18.82B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Essex Property Trust, Inc. is far larger — about 195.5× Inovio Pharmaceuticals Inc's market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ESS | INO | |
|---|---|---|
Market Cap | $18.82B | $96.26M |
Sector | Real Estate | Health |
52-Week High | $298.33 | $2.87 |
52-Week Low | $239.61 | $1.05 |
Enterprise Value | $25.54B | $67.27M |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
